Syngene International Gears Up for Q3 Reveal on 17th January; Check Key Expectations Here

Name: Stock Advisory service In India
Brand: univest
Rating: 4.4 (197000 reviews)

Posted by : sachet | Fri Jan 09 2026

Syngene International Gears Up for Q3 Reveal on 17th January; Check Key Expectations Here

Click and Sign Up to Get Live Updates on Q3 Results

Syngene International Q3 Results: one of the most significant Indian conglomerates, is set to announce its Q3 results for FY26 on 17th January 2026. Financial analysts anticipate an increase in revenue due to higher sales and a significant rise in PAT.

Table of Contents

Syngene International Q3 Results 2026 Preview

Syngene International’s revenue is expected to be in the range of ₹1,000 crore to ₹1,050 crore, with a 10% YoY increase.
Profit After Tax (PAT) is projected to grow by 8% YoY to ₹170-₹180 crore.
Syngene International’s EBITDA is expected to rise 9% YoY to ₹300 crore.
Net profit at ₹175 crore, up by 8% YoY

Syngene International Share Performance

Over the past six months, Syngene International’s share price has risen by 4.5% to ₹675.
Moreover, over the past year, the stock has increased by 6.2%.
Despite this weak short-term performance, Syngene International stock has delivered a financially sound 85% return over the past 5 years.
As of 9th January 2026, the stock traded at ₹675 per share, with a day high of ₹690 per share.

Key Factors to Watch for Syngene International

Revenue Growth & Client Pipeline: Demand from global pharma and biotech companies across discovery, development, and manufacturing services
Order Book & Long-Term Contracts: New project additions and visibility from multi-year CRAMS agreements
EBITDA & Margin Performance: Impact of operating leverage, input costs, and capacity utilisation
Profit After Tax (PAT) Trend: YoY and QoQ profitability driven by execution efficiency
Business Segment Performance: Growth momentum in discovery services, biologics, and dedicated research centres (DRCs)

Final Thoughts

Syngene International is expected to post steady Q3 FY26 performance, with ~10% revenue growth, 8% PAT growth, and stable margins. Continued focus on long-term client contracts, biologics expansion, and global pharma partnerships should support earnings visibility in FY26 and beyond.

Disclaimer: Investment in the share market is subject to risk. This news article is for informational purposes only. Conduct your own research before investing in shares and other securities.

Download the Univest iOS App or Univest Android App to get daily stock recommendations and insightful research pieces!